ML20008F747
| ML20008F747 | |
| Person / Time | |
|---|---|
| Site: | Framatome ANP Richland |
| Issue date: | 11/21/1980 |
| From: | Estey H SIEMENS POWER CORP. (FORMERLY SIEMENS NUCLEAR POWER |
| To: | Crow W NRC OFFICE OF NUCLEAR MATERIAL SAFETY & SAFEGUARDS (NMSS) |
| References | |
| 17945, NUDOCS 8104210668 | |
| Download: ML20008F747 (42) | |
Text
_
rx po-1257
^
ERON NUCLEAR COMPANY,lnc.
2101/kvn RaphirRaat P. G Bat 130.RicNat WagranM2 w,j November 21, 1980 Phone:($09) 375-8100 Telex: lS 2878
'-[aLUD%-u P1r. W. T. Crow, Section Leader
~
Uranium Process Licensing Section
'f, APR 101981
- q Uranium Fuel Licensing Branch u.s. *ocuas ucuweet
, Division of Fuel Cycle & Material Safety
?
U.S. Nuclear Regulatory Comission C
Washington, D.C.
20555 License No. SNM-1227 Docket No. 70-1257
Dear Mr. Crow:
SUBJECT:
Application to Amend License No. SNM-1227 Exxon Nuclear Company, Inc. hereby requests that License No. SNM-1227 be amended to reference this letter, thereby incorporating the proposed changes in Exxon Nuclear's SNfi-License Document, as described in the enclosed modified pages of that Document (XN-2}.
The principal changes proposed include:
1)
Exxon Nuclear Company, Inc. organization; 2)
Deletion of the specification for the use of D0P as the HEPA filter efficiency testing media (due to possible classification of D0P as a carcinogenic agent); and 3)
Allowance for the use of an alternative to in-place D0P testing of final HEPA filter installations.
Enclosed are seven copies of the modified pages of Document No. XN-2, along with a check in the amount of $1400 to cover the associated minor amendment fee.
Sincerely, H.
aul Estey, Manager Licensing & Compliance, Operating Facilities HPE:cic Enclosures (as noted) cc: Mr. W. J. Cooley (USNRC, Region V IE)
Mr. J. G. Partlow (USNRC, flaterial Control Licensing Branch) 17345 AN AFFluATE OF EXXON COMPOft ATION
i ENCLOSURE
SUMMARY
OF CHANGES IN DOCUMENT NO. XN-2 Page No.
Section No.
Change 2.3 2.2(a)
Removed the words "& Executive-in-Charge" from position title.
2.5 2.3 Removed the words "& Executive-in-Charge" from position title.
2.6 2.3.2 & 2.3.3 Removed the words "& Executive-in-Charge" from position title (5 places); removed " engineering design, development" (of nuclear fuels) from the overall responsibilities of the Vice President, Manufacturing -- these functions are the responsibility of the Vice President, Engineering
& Technology 2.12 2.3.9 Removed the words "& Executive-in-Charge" from position title.
1.18 2.3.15 Changed the Vice President to whom the Manager, Corporate Licensing & Compliance reports from "Proj ects" to " Engineering & Technology".
2.18 2.3.16 Removed the words "& Executive-in-Charge" from position title.
2.24 Fig. 2.3-1 Updated Exxon Nuclear's organization with changes that become effective 1/1/81.
2.25 Fig. 2. 3-2 Removed the words "& Executive-in-Charge" from position title.
3.11 3.1.4.2 Removed the term "DOP"; in light of the F9tential
.of DOP being classified as carcinogenic (see Attachment, " Carcinogenesis Bioassay of Di(2-Ethylhexyl)Phthalate"), and since the use of DOP for HEPA filter testing has been suspended at several filter testing facilities, it is prudent to not specify in the license conditione the testing media to be employed.
3.22 3.2 Corrected a typo.
Relocation of material, only.
3.39 & 3.40 3.41 & 3.42 3.3.1 Added an alternative (continuous gaseous effluent monitoring, in addition to continuous sampling) to in-place DOP testing of final HEPA filter installations that is considered acceptable in light of the potential of DOP being classified as carcinogenic.
~
ENCLOSURE (Continued)
Page No.
Section No.
Change 3.43 3.3.3 Modified wording to clarify that IEPA filters are normally replaced when respective ap readings reach 4 inches of water gage, and that the ap across final HEPA filters is not allcwed to exceed 4 inches of water gage.
3.61 3.11 Removed the words "& Executive-in-Charge" from position title.
A-1.1 1.1 Updated the address of Exxon Nuclear's principal offices in Bellevue, b'A (effective % mid-December, 1980).
A-2.2 2.
Updated Exxon Nuclear's organization with changes that become effective 1/1/81.
A-2.3 Fig. A.2-1 Updated Exxon Nuc2. ear's organization with changes that become effective 1/1/81.
A-4.la 4.2 & 4.25 Removed the words "& Executive-in-Charge" from position titles.
A-4.lb 4.30 Removed resume; this position has been eliminated i
in the Company reorganization.
A-4.2 4.1 Provided resume of new President & Chief Executive Officer of Exxon Nuclear (effective 1/1/81).
A-4. 3 &
4.2 Removed the words "& Executive-in-Charge" from A-4.3a position title (2 places).
A-4.6 4.5 Provided resume of new Managet, CO Plant.
2 A-4.26 4.25 Replaced resume; added page A-4.26a.
A-4.31 4.30 Removed resume; this position has been eliminated in the Company reorganization; eliminated pages A-4.31a and A-4.31b.
A-4.35 4.34 Replaced resume; added page A-4.35a.
.=y
,we w.
e--
A.~'
- j
)
4 NTP Technical Report cn the JRl4FT URAFT CARCINCGE?iESIS SICASSAY of OI(2-ETHYLHEXYL)PHTHALATE (CAS No.117-81-7)
RECElvga NOV 141980 qct Nfg F
L A. BISFING 4 g g S,
Mf;;I "$
n 9,
'O C
CCC*p O
Carcinogenesis Testing Program NATIONAL T0XICOLOGY PRCGRAM P. O. Box 12233 Research Triangle Park North Carolina 27709 NOTICE This is not a final report. Until this ORAFT is reviewed and approved by the Technical Reports Review Subcenmittee of tne NTP Board of Scientific Counselors, this ORAFT does not represent the official position of the National Toxicology Prcgram.
15 October 1980 NTP-80-37 CHHS Publicaticn Numcer (NIH) 81-1773 Public Health Service Department of Health and Human Services
M 1 * "?
a nm,m ~ nacu e
b Cepies of these ORAFT Reports are printed cnly for the purpose of sciencific peer-review and are not available for general distributicn.
Three to six r.cnths after the peer-review meeti,ng, FINAL Reports are made availabi'e frca tne Naticnal Technical Information Servica, Springfield, VA 22151 (703-557-4650).
Ccements and questiens abcut the CRAFT Naticnal Toxicology Prcgram Technical Repor en the Carcine-genesis Bicassay of Di(2-ethylhexyl)chthalate shculd be directed to Dr. J. F. Ocuglas, National Cancer Institute, Recm A-322, Landcw Eutiding, Sethesda, MD 20205 (301-496-5591).
4 e
0
~